EUTECNIQAtlas

Every page of EUTECNIQ on one mapArrow keys move through results · Enter opens · Esc closes

Reference library USP, Ph. Eur. and FDA BAM text Peer-reviewed methods Computed figures

Microorganisms in botanicals

Plant materials carry bacteria, yeasts and molds from soil, water, animals and people, and a few of them cause infection or form toxins. This page lists those organisms, the pharmacopeial limits that apply to them, and how laboratories count, detect and identify them.

10⁵ cfu/gUSP ⟨2023⟩ recommended total aerobic count for dried or powdered botanicals
15–300Colonies per plate that FDA's aerobic plate count now uses; the range was 25–250 until March 2025
0.640Water activity at which the xerophilic molds Aspergillus penicillioides and Xeromyces bisporus still grew as mycelium
~20,000Droplets of about 1 nL into which droplet digital PCR splits a 20 µL reaction

USP 35–NF 30 ⟨2023⟩ Table 2; FDA BAM Chapter 3 (January 2026), revision history; Stevenson et al., ISME J 2015; Hindson et al., Anal Chem 2011.

Status. EUTECNIQ is in formation. It operates no microbiology laboratory and has tested no samples; methods here are described from their published texts.

Course: Microbiology of botanicals covers kill steps, acid tolerance, biofilms, cells that do not form colonies, and has plate-count and growth-window calculators. Related: mycotoxins and other contaminants · process hygiene · quality system

Three-dimensional rendering of a rack of five dilution tubes and three agar plates: one crowded with colonies, one with a countable number, and one with only a few.
  1. 1 Tenfold serial dilution
  2. 2 Spread plates after incubation

Tenfold serial dilution and spread plates, rendered by EUTECNIQ; colony numbers are illustrative.

Organisms

Bacteria of concern

FDA's Bad Bug Book records Bacillus cereus in soil and vegetation, Listeria monocytogenes in soil and decaying vegetation, and Cronobacter in herbs and spices; Salmonella survives well in spices. Some of these organisms cause infection. Others harm through a toxin: Staphylococcus aureus enterotoxins and the emetic toxin of B. cereus form in the food, and C. botulinum neurotoxin forms during growth.

Two groups in the table are not single pathogens. E. coli and the bile-tolerant Gram-negative bacteria mark contamination and hygiene; Pseudomonas aeruginosa and the Burkholderia cepacia complex matter mainly in water-based liquids and topical products.

Bacteria relevant to botanical materials: type, where they occur, hazard and the limit or test that applies
OrganismGram stain and formWhere it occursHazardLimit or test
Salmonella spp.Gram-negative rod; no spores; EnterobacteriaceaeSurvives in low-moisture foods; spices have carried large outbreaksInfectionAbsent in 10 g (USP ⟨2023⟩); absent in 25 g (Ph. Eur. 5.1.8); FDA BAM Ch. 5
Escherichia coliGram-negative rod; EnterobacteriaceaeIntestine of humans and warm-blooded animals; proposed as an indicator of fecal contamination in 1892Indicator; most strains not pathogensAbsent in 10 g (USP ⟨2023⟩); absent in 1 g, or 10³ cfu/g for herbal teas (Ph. Eur.)
Shiga toxin-producing E. coliGram-negative rodOutbreaks traced to lettuce, spinach, sprouts and unpasteurized juiceInfection; Shiga toxinsNo USP ⟨2023⟩ criterion; FDA BAM Ch. 4A
Staphylococcus aureusGram-positive cocci in grape-like clustersNose, throat, hair and skin of 50% or more of healthy people; food handlersHeat-stable enterotoxins formed in foodTested in USP ⟨2022⟩; no ⟨2023⟩ criterion; not detected in 10 g (NSF/ANSI 173)
Bacillus cereusGram-positive large rod; facultatively anaerobic; endosporesSoil and vegetationDiarrheal toxin made in the intestine; emetic toxin (cereulide) made in foodNo USP ⟨2023⟩ criterion; FDA BAM Ch. 14
Clostridium perfringensGram-positive rod; anaerobic but aerotolerant; heat-resistant sporesSoil, sediments and animal intestinesEnterotoxinClostridia test with an 80 °C, 10 min heated portion (USP ⟨2022⟩, ⟨62⟩); FDA BAM Ch. 16
Clostridium botulinumGram-positive rod; anaerobic; heat-resistant sporesCultivated and forest soils; sedimentsNeurotoxin formed during growthNo count limit; growth controlled by water activity, pH, temperature and oxygen (next sections)
Listeria monocytogenesGram-positive rod; facultative; motileSoil, decaying vegetation, moist environments; persists in food plants; grows below 1 °CInfection; among the leading causes of death from foodborne illnessNo USP ⟨2023⟩ criterion; FDA BAM Ch. 10
Cronobacter spp.Gram-negative motile rodIsolated from herbs, spices, cereals and rice; survives up to 2 years in powdered infant formula (aw about 0.2)Infection, chiefly in infantsFDA BAM Ch. 29
Bile-tolerant Gram-negative bacteriaGram-negative; includes EnterobacteriaceaeGroup test, not one speciesHygiene indicator10³ cfu/g, dried botanicals (USP ⟨2023⟩); 10² or 10⁴ (Ph. Eur. B or C); USP ⟨62⟩
Pseudomonas aeruginosaGram-negative; forms biofilmsSoil and water; most human- or animal-impacted environmentsOpportunistic infectionAbsent in 1 g or 1 mL for cutaneous, oromucosal and nasal drug products (USP ⟨1111⟩); cetrimide agar (⟨62⟩)
Burkholderia cepacia complexGram-negative group of speciesSurvives or multiplies in non-sterile water-based products; resists some preservativesOpportunistic infection, especially in immunocompromised peopleUSP ⟨60⟩ (published December 1, 2019), which FDA recommends

FDA Bad Bug Book, 2nd ed. (2012): Salmonella, EHEC, S. aureus, B. cereus, C. perfringens, C. botulinum, L. monocytogenes and Cronobacter chapters; FDA BAM Ch. 4 (October 2020), introduction; USP 35–NF 30 ⟨2022⟩, ⟨2023⟩, ⟨62⟩, ⟨1111⟩; Ph. Eur. 5.1.8 (10th ed.); AHPA comparison of microbial limits (June 2022) for NSF/ANSI 173; Diggle and Whiteley, Microbiology 2020; FDA statement on B. cepacia complex in non-sterile water-based drugs.

Fungi

Yeasts and molds

FDA's Bacteriological Analytical Manual notes that most foodborne molds can grow at a water activity of 0.85 or less, while yeasts generally need more water, and that most mycotoxins are stable compounds not destroyed by processing. A yeast-and-mold count therefore says nothing about toxin already formed; mycotoxins need their own assays, covered on the contaminants page.

Mold genera found on plant materials, the mycotoxins named for them, and counting notes
GenusMycotoxins named for the genusCounting note
AspergillusAflatoxins (A. flavus, A. parasiticus); ochratoxin A; patulinDichloran 18% glycerol agar (aw 0.955) preferred when the sample's aw is below 0.95
PenicilliumOchratoxin A; patulinExperienced analysts identify it on the plate at 10–30× magnification; malt extract agar for identification (FDA BAM Ch. 18)
FusariumDeoxynivalenol, nivalenol, T-2 and HT-2 toxins, zearalenone, fumonisinsCommon in soil (WHO)
AlternariaAlternariol, alternariol monomethyl ether, tenuazonic acid, altertoxins, tentoxinEFSA found the toxins in grains, tomato products, sunflower seeds and fruit
MucorNone among the toxins WHO listsA "spreader" that can overgrow plates; dichloran and rose bengal in DRBC agar slow it
YeastsNone in WHO's list; FDA BAM says "possibly yeasts"Counted with molds as TYMC; generally need higher water activity than molds

FDA BAM Ch. 18, Yeasts, Molds and Mycotoxins (April 2001), introduction and media appendix; WHO fact sheet, Mycotoxins (October 2, 2023); EFSA CONTAM Panel, Alternaria toxins in feed and food, EFSA J 2011;9(10):2407.

Cell forms

Spores and vegetative cells

Bacillus and Clostridium species can form endospores, dormant cells that survive drying and heat that kill growing (vegetative) cells. The pharmacopeial Clostridia test uses this: one portion of the sample is heated to 80 °C for 10 min and cooled, the other is not, and both are cultured anaerobically.

Why bacterial endospores resist heat and radiation compared with vegetative cells
Feature of the endosporeEffect
Core water content much lower than in a growing cellMain determinant of wet-heat resistance
α/β-type small acid-soluble proteins saturate the DNAProtect DNA against wet heat, dry heat and UV
Large pool of dipicolinic acid in the coreContributes to UV resistance
Killed by dry heat, UV and gamma radiation through DNA damageKill steps for spores need far more than for vegetative cells; see the Academy course

Setlow P, J Appl Microbiol 2006;101:514–525 (Bacillus subtilis spores); USP 35–NF 30 ⟨2022⟩ and ⟨62⟩, Clostridia.

A bacterial endospore is about the size of a bacterium; a yeast cell or a hyphal width is several times largerDrawn to relative scale
Five microbial forms drawn at the same magnification with a 5 micrometer scale bar: a rod-shaped bacterium about 1 by 2 micrometers, a grape-like cluster of round cocci about 1 micrometer across, an oval bacterial endospore about 0.85 by 1.45 micrometers with its layers shown schematically, a budding yeast cell about 4 micrometers across with a smaller bud, and a fungal hypha 3 micrometers wide divided by cross walls and branching once.
Sizes: Milo and Phillips, Cell Biology by the Numbers (BioNumbers), E. coli and S. cerevisiae; Monteiro et al., Nat Commun 2015 (S. aureus); Carrera et al., J Appl Microbiol 2007 (Bacillus spores); Lehmann et al., Sci Rep 2019 (hyphal widths). Internal detail schematic. Illustration by EUTECNIQ. Full-size SVG
Growth limits

Water activity and growth

Each pathogen has a minimum water activity (aw) below which it does not grow. FDA's table measured each limit with salt as the humectant and the other factors near optimal, so combined stresses narrow the windows. No growth is not death: Salmonella and Cronobacter survive in dry foods, and USP ⟨2023⟩ says only that low-aw products "will not be susceptible to microbial growth during their shelf life."

Minimum water activity, pH and temperature for growth, oxygen requirement and spore formation
OrganismMin. awMin. pHGrowth range, °COxygenSpores
C. botulinum type E, non-proteolytic B and F0.975.03.3–45AnaerobeYes
Pathogenic E. coli0.954.06.5–49.4FacultativeNo
Salmonella spp.0.943.75.2–46.2FacultativeNo
C. botulinum type A, proteolytic B and F0.9354.610–48AnaerobeYes
C. perfringens0.935.010–52AnaerobeYes
B. cereus0.924.34–55FacultativeYes
L. monocytogenes0.924.4−0.4–45FacultativeNo
S. aureus, toxin formation0.854.010–48FacultativeNo
S. aureus, growth0.834.07–50FacultativeNo
Most foodborne molds≤ 0.85210–35, a few beyondMostly aerobicFungal spores
Xerophilic A. penicillioides, X. bisporus0.640–––Fungal spores

FDA, Fish and Fishery Products Hazards and Controls Guidance, Appendix 4, Table A-1 (bacteria; aw with salt); FDA BAM Ch. 18 (molds: aw 0.85 or less, pH 2 to above 9, 10–35 °C); Stevenson et al., ISME J 2015;9:1333–1351 (0.640, with mixed solutes; earlier limit about 0.65); spore formers as named in the FDA Bad Bug Book; the others listed do not form spores. The Academy course has an interactive growth-window explorer built on Table A-1.

Specifications

Pharmacopeial microbial limits

USP ⟨2023⟩ recommends limits by how processed a material is, and applies them only when the monograph is silent. It states that coliform or Enterobacteriaceae counts "will not be an appropriate general microbiological criterion for botanicals." Ph. Eur. 5.1.8 uses three categories; its maximum acceptable count is five times the stated criterion.

USP ⟨2023⟩ Tables 2 and 3, recommended limits (cfu per g or mL), USP 35–NF 30 text
MaterialTAMC, NMTTYMC, NMTBTGN, NMTAbsence required
Dried or powdered botanicals10⁵10³10³Salmonella and E. coli in 10 g
Powdered botanical extracts10⁴10³–Salmonella and E. coli in 10 g
Tinctures10⁴10³––
Fluidextracts10⁴10³––
Infusions and decoctions10²10––
Nutritional supplements with botanicals10⁴10³–Salmonella and E. coli in 10 g
Botanicals to be treated with boiling water before use10⁵10³–E. coli in 10 g
Other raw materials and supplement ingredients (Table 3)10³10²Not specifiedE. coli in 10 g
Supplements with synthetic or highly refined ingredients (Table 3)10³10²Not specifiedE. coli in 10 g

USP 35–NF 30, ⟨2023⟩ Tables 2 and 3; same values for dried botanicals, extracts and supplements in AHPA's June 2022 comparison. Later editions revised the boiling-water row (compared on the Academy page); USP lists 2025 versions of ⟨2021⟩–⟨2023⟩, so confirm the current official text in USP–NF. TAMC: total aerobic microbial count; TYMC: total combined yeasts and molds count; BTGN: bile-tolerant Gram-negative bacteria; NMT: not more than.

Ph. Eur. 5.1.8 categories (cfu/g) and NSF/ANSI 173 values as tabulated by AHPA
CategoryTAMCTYMCBTGNE. coliSalmonellaS. aureus
Ph. Eur. A: herbal teas used with boiling water10⁷ (max 5 × 10⁷)10⁵ (max 5 × 10⁵)–10³ cfu/gAbsent in 25 g–
Ph. Eur. B: extracts and pre-treated herbal drugs10⁴10²10²Absent in 1 gAbsent in 25 g–
Ph. Eur. C: where processing cannot meet category B10⁵10⁴10⁴Absent in 1 gAbsent in 25 g–
NSF/ANSI 173, finished product, non-extract10⁷10⁵10⁴10² cfu/g*Not detected in 10 gNot detected in 10 g
NSF/ANSI 173, finished product, extract10⁴10³10²Not detected in 10 gNot detected in 10 gNot detected in 10 g

Ph. Eur. 10th ed., 5.1.8 (category descriptions abbreviated; maximum = 5 × criterion). NSF/ANSI 173 values as listed in AHPA, Recommended Microbial Limits for Botanical Ingredients, comparison table (June 2022); *if E. coli is confirmed, colonies are tested for enterovirulent E. coli, which has zero tolerance. For drug products, harmonized USP ⟨61⟩ reads a criterion of 10¹ cfu as a maximum acceptable count of 20, 10² as 200, and so on.

Compendial methods

What the USP tests do

The supplement chapters ⟨2021⟩ and ⟨2022⟩ count and detect; the drug chapters ⟨61⟩ and ⟨62⟩ do the same with harmonized media and incubation. Before any count is trusted, a suitability test spikes the sample with known organisms and checks they are recovered, because many botanicals inhibit growth.

Principles of USP microbial enumeration and specified-organism tests
ChapterPurposeMedia and incubationReadout and suitability
⟨2021⟩ (USP 35–NF 30)TAMC and TYMC of supplements; 10 g or 10 mL brought to 100 mL (1:10)Soybean–casein digest agar, 30–35 °C, 48–72 h; Sabouraud dextrose agar, 20–25 °C, 5–7 daysDilute to 30–300 colonies per 1 mL; blank 1:10 plates reported as fewer than 10 per g; more than 70% recovery in preparatory testing
⟨61⟩ (harmonized, official May 1, 2025)TAMC and TYMC of nonsterile drug productsMembrane filtration (pore ≤ 0.45 µm), pour plate (1 mL in 15–20 mL agar) or spread plate (≥ 0.1 mL); 30–35 °C, 3–5 days and 20–25 °C, 5–7 daysPlates under 250 (TAMC) or 50 (TYMC) colonies; inoculum ≤ 100 cfu; recovery within a factor of 2; MPN only for TAMC when no other method works
⟨2022⟩ (USP 35–NF 30)Absence of Salmonella, E. coli, S. aureus and Clostridium; 10 g, with an optional 25 g retest of a doubtful resultSalmonella: Rappaport–Vassiliadis broth, then brilliant green, XLD or Hektoen agar. E. coli: MacConkey broth at 42–44 °C, then MacConkey agar. Clostridium: 80 °C for 10 min, reinforced clostridial medium, anaerobic, 35–37 °C, 48 hSuspect colonies confirmed by identification tests
⟨62⟩ (harmonized)Bile-tolerant Gram-negatives, E. coli, Salmonella, P. aeruginosa, S. aureus, Clostridia, Candida albicansEnterobacteria enrichment broth Mossel then violet red bile glucose agar; cetrimide agar; mannitol salt agar; Columbia agar (anaerobic); Sabouraud media; mostly 30–35 °CS. aureus: yellow or white colonies with a yellow zone; Salmonella: red colonies on XLD, with or without black centers

USP 35–NF 30 ⟨2021⟩, ⟨2022⟩, ⟨62⟩; USP ⟨61⟩ Stage 4 harmonized text, official May 1, 2025 (USP harmonization page).

Enumeration

Plate counts

A colony-forming unit (cfu) is any cell or clump that grows into one visible colony. The sample is diluted in tenfold steps until a plate holds a countable number. FDA's estimate is a weighted average: total colonies on all countable plates divided by the total amount of sample those plates received. Results are rounded to two significant figures.

Countable colony ranges per plate in different methods
MethodCountable colonies per plate
FDA BAM aerobic plate count (pour plate, since March 2025)15–300
ISO 4833, as cited by FDA BAM15–300
APHA, as cited by FDA BAM; BAM before March 202525–250
USDA and AOAC, as cited by FDA BAM30–300
USP ⟨2021⟩ (USP 35–NF 30)30–300
Harmonized USP ⟨61⟩: TAMC / TYMC< 250 / < 50
FDA BAM yeasts and molds (spread plate, 25 °C, 5 days)10–150
Spiral plater, one inoculation (per mL of sample)500–500,000

FDA BAM Ch. 3, Aerobic Plate Count (January 2026), introduction, Sections C–D and the spiral plate method; FDA BAM Ch. 18; USP 35–NF 30 ⟨2021⟩; harmonized USP ⟨61⟩ (2025).

Four countable plates from two dilutions give one weighted count: 22,000 cfu/g in this exampleWorked example, schematic
A sample bag holding 10 grams of botanical in 90 milliliters of diluent makes a 1 to 10 homogenate. Ten milliliters are carried into 90 milliliters of diluent three times, giving tenfold dilutions to 1 in 10,000. One milliliter of each of three dilutions is poured with molten agar into two dishes; after incubation the dishes hold 212 and 236, 25 and 19, and 2 and 3 colonies. Only dishes with 15 to 300 colonies are used, and the count works out to 22,000 colony-forming units per gram. Side panels compare pour plates, spread plates and membrane filtration.
Procedure after FDA BAM Chapter 3 (January 2026) and Chapter 18; harmonized USP <61> (official May 1, 2025); USP 35–NF 30 <2021> and <2023>. Colony counts are an invented example. Illustration by EUTECNIQ. Full-size SVG
Statistics

Most probable number and detection

The most probable number (MPN) method inoculates replicate tubes at several dilutions and records which grow. It assumes random distribution and that any tube receiving one viable cell turns positive; the MPN is the concentration λ that makes the observed pattern most likely, solving Σ gjmj/(1 − e−λmj) = Σ tjmj. FDA notes it is particularly useful below about 100 organisms per g.

The same Poisson model sets what a presence or absence test can see: the chance that a portion of mass m holds at least one cell is 1 − e−cm. A negative 10 g test is consistent with a lot at 0.1 cfu/g about 37% of the time.

Three-tube MPN solved from the equation, checked against FDA BAM Appendix 2, Table 1 (0.1, 0.01 and 0.001 g per tube)
Positive tubesMPN/g, solved hereMPN/g, BAM Table 1BAM 95% interval
1-0-03.573.60.17–18
2-1-014.7153.7–42
3-0-023.1234.6–94
3-1-042.7439–180
3-2-093.39318–420

FDA BAM Appendix 2, Most Probable Number from Serial Dilutions (August 2023), introduction and Table 1. Solved by bisection on the likelihood equation; BAM rounds to two significant figures.

An absence result in 10 g reaches 95% detection only when the lot holds about 0.3 cfu/g or moreComputed, Poisson model
Probability that an analytical portion of 1, 10, 25 or 375 g contains at least one target cell, as a function of concentration, assuming random (Poisson) distribution0%25%50%75%100%0.00010.0010.010.1110Concentration of the target in the lot, cfu/g (log scale)Probability the portion holds at least one cell95%1 g: Ph. Eur. E. coli test portion1 g: 95% detection at 3.00 cfu/g10 g: USP ⟨2022⟩ test portion10 g: 95% detection at 0.30 cfu/g25 g: Ph. Eur. Salmonella; USP retest25 g: 95% detection at 0.12 cfu/g375 g: FDA BAM composite (15 × 25 g)375 g: 95% detection at 0.008 cfu/g375 g95% at 0.008 cfu/g25 g95% at 0.12 cfu/g10 g95% at 0.30 cfu/g1 g95% at 3.00 cfu/gProbability that an analytical portion of 1, 10, 25 or 375 g contains at least one target cell, as a function of concentration, assuming random (Poisson) distribution0%25%50%75%100%0.00010.0010.010.1110Concentration of the target in the lot, cfu/g (logscale)Probability the portion holds at least one cell95%1 g: Ph. Eur. E. coli test portion1 g: 95% detection at 3.00 cfu/g10 g: USP ⟨2022⟩ test portion10 g: 95% detection at 0.30 cfu/g25 g: Ph. Eur. Salmonella; USP retest25 g: 95% detection at 0.12 cfu/g375 g: FDA BAM composite (15 × 25 g)375 g: 95% detection at 0.008 cfu/g375 g: 95% at 0.008 cfu/g25 g: 95% at 0.12 cfu/g10 g: 95% at 0.30 cfu/g1 g: 95% at 3.00 cfu/g
P = 1 − e−cm; 95% at c = ln 20 / m. Assumes random distribution and that every portion holding a viable cell tests positive (FDA BAM Appendix 2 assumptions). Clustered contamination, as in spices, lowers detection further. Portion sizes: Ph. Eur. 5.1.8, USP ⟨2022⟩, FDA BAM Ch. 5.
Detection

Enrichment and selective media

Detection methods for pathogens run in stages: a nonselective pre-enrichment, selective broths that favor the target over competitors, differential agars on which its colonies look distinct, then screening slants and identification tests. FDA dilutes allspice, cinnamon and oregano 1:100 and cloves 1:1000, because no method neutralizes their toxicity to Salmonella culture.

FDA's culture method for Salmonella in spices needs four incubations before a presumptive resultFDA method text
FDA BAM Chapter 5 culture workflow for Salmonella in spices: pre-enrichment, selective enrichment, selective plating, TSI and LIA screening and identification, with incubation times1Pre-enrichment25 g spice + 225 mLTSB (1:10); 60 min atroom temperature, pH6.8 ± 0.2; 24 ± 2 h at35 ± 2 °COnion and garlic: TSB + 0.5%K₂SO₃. Allspice, cinnamon,oregano 1:100; cloves 1:10002Selectiveenrichment0.1 mL → 10 mLRappaport–Vassiliadis,42 ± 0.2 °C; 1 mL → 10mL tetrathionate, 43 °C(high microbial load) or35 °C (low); 24 ± 2 hOptional rapid screen of thepre-enrichment first: FDAqPCR or LAMP3Selective plating10 µL of each brothstreaked on bismuthsulfite, XLD andHektoen enteric agars;24 ± 2 h at 35 °C(bismuth sulfitere-read at 48 h)Typical colonies: pink with orwithout black centers (XLD);blue-green (HE); brown toblack (BS)4Screening slantsColonies picked totriple sugar iron andlysine iron agar; 24 ± 2h at 35 °CTypical: alkaline (red) slant,acid (yellow) butt in TSI;alkaline (purple) butt in LIA5IdentificationUrease, polyvalent Oand H serology,biochemicalidentification;whole-genomesequencing withSeqSero for serotypeA minimum of 6 TSI culturesper 25 g analytical unit or 375g composite0 h24 h48 h72 h96 h120 h144 hIncubation time to a presumptive TSI/LIA result: about 96 to 120 hIncubation to a presumptive result on TSI and LIA: about 96–120 h (sum of the steps above)FDA BAM Chapter 5 culture workflow for Salmonella in spices, step by step, with incubation times1Pre-enrichment25 g spice + 225 mL TSB (1:10); 60 min at roomtemperature, pH 6.8 ± 0.2; 24 ± 2 h at 35 ± 2 °COnion and garlic: TSB + 0.5% K₂SO₃. Allspice, cinnamon,oregano 1:100; cloves 1:10002Selective enrichment0.1 mL → 10 mL Rappaport–Vassiliadis, 42 ± 0.2 °C; 1mL → 10 mL tetrathionate, 43 °C (high microbialload) or 35 °C (low); 24 ± 2 hOptional rapid screen of the pre-enrichment first: FDAqPCR or LAMP3Selective plating10 µL of each broth streaked on bismuth sulfite, XLDand Hektoen enteric agars; 24 ± 2 h at 35 °C(bismuth sulfite re-read at 48 h)Typical colonies: pink with or without black centers(XLD); blue-green (HE); brown to black (BS)4Screening slantsColonies picked to triple sugar iron and lysine ironagar; 24 ± 2 h at 35 °CTypical: alkaline (red) slant, acid (yellow) butt in TSI;alkaline (purple) butt in LIA5IdentificationUrease, polyvalent O and H serology, biochemicalidentification; whole-genome sequencing withSeqSero for serotypeA minimum of 6 TSI cultures per 25 g analytical unit or375 g compositeIncubation to a presumptive TSI/LIA result: about 96–120h
FDA BAM Ch. 5, Salmonella (October 2026 edition), Sections C.10, D, E.1–E.11 and F. Times are incubation only.
Selective and differential media named in FDA and USP methods, with the reaction each method describes
MediumTargetReaction described by the method
Xylose lysine desoxycholate (XLD) agarSalmonellaPink colonies with or without black centers (BAM); red with or without black centers (USP ⟨62⟩)
Hektoen enteric agarSalmonellaBlue-green to blue colonies with or without black centers
Bismuth sulfite agarSalmonellaBrown, gray or black colonies, sometimes with a metallic sheen
Triple sugar iron and lysine iron agar slantsSalmonella screeningAlkaline (red) slant and acid (yellow) butt in TSI, with or without H₂S; alkaline (purple) butt in LIA
MacConkey broth at 42–44 °CE. coliGrowth subcultured to MacConkey agar; colonies need identification
Violet red bile glucose agarBile-tolerant Gram-negativesAny growth counts
Cetrimide agarP. aeruginosaGrowth indicates possible presence; confirm
Mannitol salt agarS. aureusYellow or white colonies surrounded by a yellow zone
DRBC and DG18 agarsMolds and yeastsDRBC slows spreading molds; DG18 (aw 0.955) for samples below aw 0.95

FDA BAM Ch. 5 (October 2026), Section E.7–E.9; FDA BAM Ch. 18 media appendix; USP 35–NF 30 ⟨2022⟩ and ⟨62⟩.

Molecular methods

Real-time and digital PCR

Real-time PCR (qPCR) reads fluorescence every cycle. The threshold cycle (Ct) falls by about 3.3 cycles per tenfold more target at 100% efficiency; a standard curve gives the efficiency, E = 10−1/slope − 1. PCR also detects DNA of dead cells unless a dye such as propidium monoazide removes it. FDA uses qPCR or LAMP to screen the 24 h Salmonella pre-enrichment: negatives are reported negative, positives go to culture. Validated qPCR matrices include black and white pepper, cumin, paprika, basil and oregano.

Droplet digital PCR splits a 20 µL reaction into about 20,000 droplets and counts positive droplets at the end. With p the positive fraction, copies per droplet λ = −ln(1 − p), with no standard curve.

Each tenfold step in starting target shifts the curve by 3.45 cycles at 95% efficiencyComputed, logistic model
Computed real-time PCR amplification curves for five tenfold standards with a fixed threshold, and the standard curve of threshold cycle against log starting copies0.000.250.500.751.00010203040PCR cycleFluorescence (fraction of plateau)Threshold1e+06 starting copies: Ct 17.4Ct 17.41e+05 starting copies: Ct 20.8Ct 20.81e+04 starting copies: Ct 24.3Ct 24.31e+03 starting copies: Ct 27.7Ct 27.71e+02 starting copies: Ct 31.2Ct 31.2106​ copies · Ct 17.4105​ copies · Ct 20.8104​ copies · Ct 24.3103​ copies · Ct 27.7102​ copies · Ct 31.21520253023456log₁₀ starting copiesThreshold cycle, Ctlog copies 6: Ct 17.40log copies 5: Ct 20.84log copies 4: Ct 24.29log copies 3: Ct 27.74log copies 2: Ct 31.19slope -3.45 cycles per log₁₀E = 10−1/slope​ − 1 = 95%Computed real-time PCR amplification curves and standard curve0.000.250.500.751.00010203040PCR cycleFluorescence (fraction of plateau)Threshold1e+06 starting copies: Ct 17.4Ct 17.41e+05 starting copies: Ct 20.8Ct 20.81e+04 starting copies: Ct 24.3Ct 24.31e+03 starting copies: Ct 27.7Ct 27.71e+02 starting copies: Ct 31.2Ct 31.2106​ copies · Ct 17.4105​ copies · Ct 20.8104​ copies · Ct 24.3103​ copies · Ct 27.7102​ copies · Ct 31.21520253023456log₁₀ starting copiesThreshold cycle, Ctlog copies 6: Ct 17.40log copies 5: Ct 20.84log copies 4: Ct 24.29log copies 3: Ct 27.74log copies 2: Ct 31.19slope -3.45 cycles per log₁₀E = 10−1/slope​ − 1 = 95%
Model: F(c) = Fmax / (1 + (Fmax/F0 − 1)(1 + E)−c) plus background, E = 0.95, F0 proportional to starting copies; threshold 0.1 of plateau. Sigmoid fitting: Rutledge, Nucleic Acids Res 2004. Efficiency relation and the −3.32 slope at 100%: Svec et al., Biomol Detect Quantif 2015. Illustrative values, not instrument data.
Droplet digital PCR: copies in a 20 µL reaction from the fraction of 20,000 droplets that are positive
Positive dropletspλ = −ln(1 − p), copies per dropletCopies per reaction (× 20,000)
200.0010.001020
4,0000.200.2234,463
12,0000.600.91618,326
19,9800.9996.91138,155

Hindson et al., Anal Chem 2011;83:8604–8610 (about 20,000 droplets of about 1 nL from 20 µL; Poisson correction; range from one copy to about 100,000 copies). At p = 0.999 the estimate rests on 20 negative droplets and is imprecise. Nocker et al., J Microbiol Methods 2006 (propidium monoazide). FDA BAM Ch. 5, Section D and Appendix A.

Identification

Rapid screens and identification

ATP bioluminescence measures all ATP present, microbial or not, so on plant material it reports plant residue as well as microbes. MALDI-TOF identifies an isolated colony by matching its protein mass fingerprint to a database. Sequencing reads marker genes or whole genomes. Each needs the growth or enrichment step before it, which sets most of the time to result.

Rapid and identification methods: what each measures, its resolution and its main limitation
MethodWhat it measuresResolution and speedMain limitation
ATP bioluminescenceLight from luciferase acting on ATP, in relative light unitsImmediate; no identificationCannot separate microbial from non-microbial ATP
MALDI-TOF mass spectrometryProtein fingerprint over m/z of about 2,000–20,000 (proteins of about 2–20 kDa), mostly ribosomal proteinsGenus or species of an isolate in minutesOnly organisms whose spectra are in the database
16S rRNA gene sequencingAbout 1,500 bp gene; 500–525 bp minimum for diagnostic useGenus in over 90% of isolates; species in 65–83%; species call needs more than 99% similarityPoor resolution in some groups, including Enterobacteriaceae and B. cereus / B. anthracis
ITS sequencing (fungi)Nuclear ribosomal internal transcribed spacerHighest probability of correct identification across fungi of six regions testedWeaker in some groups; supplementary barcodes proposed
Amplicon sequencing of a sample16S or ITS reads from all DNA in the sampleCommunity profile without cultureHost (plant) sequences compete; PCR clamps can block them. Counts DNA, not live cells
Whole-genome sequencingComplete genome of an isolateFDA uses it with SeqSero to assign Salmonella serotypesNeeds a pure isolate

Kotsiou et al., Antimicrob Resist Infect Control 2026;15:44; Singhal et al., Front Microbiol 2015;6:791; Janda and Abbott, J Clin Microbiol 2007;45:2761–2764; Schoch et al., PNAS 2012;109:6241–6246; Lundberg et al., Nat Methods 2013;10:999–1002; FDA BAM Ch. 5, Section F.

Incubation sets the pace: a molecular screen can report a negative after one day, culture takes two to sevenMethod texts
Incubation time before a result for seven microbiological methods, from the methods' own text01 d2 d3 d4 d5 d6 d7 dDays of incubation before the result can be readAerobic plate count, FDA BAM Ch. 3Aerobic plate count, FDA BAM Ch. 3: 48 ± 2 h at 35 °C48 ± 2 h at 35 °CTAMC, USP <2021> (USP 35–NF 30)TAMC, USP ⟨2021⟩ (USP 35–NF 30): 48–72 h at 30–35 °C48–72 h at 30–35 °CTAMC, harmonized USP <61>TAMC, harmonized USP ⟨61⟩: 3–5 days at 30–35 °C3–5 days at 30–35 °CYeasts and molds, FDA BAM Ch. 18Yeasts and molds, FDA BAM Ch. 18: 5 days at 25 °C5 days at 25 °CTYMC, USP <2021> and <61>TYMC, USP ⟨2021⟩ and ⟨61⟩: 5–7 days at 20–25 °C5–7 days at 20–25 °CSalmonella culture to TSI/LIA, BAM Ch. 5Salmonella culture to TSI/LIA, BAM Ch. 5: four incubations of 24 h; bismuth sulfite plates up to 48 hfour incubations of 24 h; bismuth sulfite plates up to 48 hSalmonella qPCR or LAMP screen, BAM Ch. 5Salmonella qPCR or LAMP screen, BAM Ch. 5: after the 24 h pre-enrichment; run time not statedafter the 24 h pre-enrichment; run time not statedIncubation time before a result for seven microbiological methods, from the methods' own text01 d2 d3 d4 d5 d6 d7 dDays of incubation before the result can be readAerobic plate count, FDA BAM Ch. 3Aerobic plate count, FDA BAM Ch. 3: 48 ± 2 h at 35 °C48 ± 2 h at 35 °CTAMC, USP <2021> (USP 35–NF 30)TAMC, USP ⟨2021⟩ (USP 35–NF 30): 48–72 h at 30–35 °C48–72 h at 30–35 °CTAMC, harmonized USP <61>TAMC, harmonized USP ⟨61⟩: 3–5 days at 30–35 °C3–5 days at 30–35 °CYeasts and molds, FDA BAM Ch. 18Yeasts and molds, FDA BAM Ch. 18: 5 days at 25 °C5 days at 25 °CTYMC, USP <2021> and <61>TYMC, USP ⟨2021⟩ and ⟨61⟩: 5–7 days at 20–25 °C5–7 days at 20–25 °CSalmonella culture to TSI/LIA, BAM Ch. 5Salmonella culture to TSI/LIA, BAM Ch. 5: four incubations of 24 h; bismuth sulfite plates up to 48 hfour incubations of 24 h; bismuth sulfite plates up to 48 hSalmonella qPCR or LAMP screen, BAM Ch. 5Salmonella qPCR or LAMP screen, BAM Ch. 5: after the 24 h pre-enrichment; run time not statedafter the 24 h pre-enrichment; run time not stated
Incubation times as written in FDA BAM Ch. 3 (Jan 2026), Ch. 5 (Oct 2026), Ch. 18 (Apr 2001); USP 35–NF 30 ⟨2021⟩; harmonized USP ⟨61⟩ (2025). Excludes sample preparation, confirmation and reporting.
Validation

Validating alternative methods

A rapid method replaces a compendial or reference method only after it is shown to give equivalent or better results in the matrix tested. USP ⟨1223⟩ asks whether the alternative "will yield results equivalent to, or better than" the compendial method and sets the parameters by test type. ISO 16140-2 gives the protocol for food-chain methods, and FDA requires verification for any matrix not already validated.

USP ⟨1223⟩ validation parameters by type of test (USP 35–NF 30 text)
ParameterQualitative (presence or absence)Quantitative (counts)
Accuracy, precision, quantification limit, linearity, operational rangeNoYes
Specificity, detection limit, robustness, repeatability, ruggednessYesYes
Frameworks for validating alternative microbiological methods
FrameworkScopeKey requirement
USP ⟨1223⟩Alternatives to USP microbiological testsCounts at least as high as the compendial method, or not less than 70% of its estimate; overlapping 95% intervals for detection limits
ISO 16140-2:2016, Amd 1:2024Alternative, mostly proprietary, methods for microbiology in the food chainMethod comparison study and interlaboratory study, for qualitative and quantitative methods; the amendment revises relative level of detection and relative trueness calculations
AOAC Performance Tested MethodsProprietary test kitsDeveloper study plus an independent laboratory study, expert review, annual renewal
FDA Foods ProgramFDA laboratory methodsVerification or validation under FDA's microbiology method validation guidelines for matrices not listed as validated

USP 35–NF 30 ⟨1223⟩, Table 1 and text (the chapter has since been revised; check current USP–NF); ISO 16140-2:2016 scope (preview of EN ISO 16140-2) and ISO 16140-2:2016/Amd 1:2024 title; AOAC Research Institute, Performance Tested Methods program page; FDA BAM Ch. 5, Section D.

EUTECNIQ

Where EUTECNIQ would work

Proposed EUTECNIQ's planned laboratory would run compendial counts and absence tests with documented method suitability for each botanical, and would adopt rapid methods only after verification in that matrix. Until then, testing would be placed with qualified laboratories.

Related: Academy: Microbiology of botanicals · Process hygiene · Contaminants and mycotoxins · Quality system · Reading a certificate of analysis

Health information notice

These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.

Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.

EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.

Ready to check what you take?

Free tools built on published reference values, each with its sources and its limits. Your lists stay in your browser.